Oramed’s oral insulin succeeds in study, shares jump

Oramed’s oral insulin succeeds in study, shares jump

(Reuters) – Oramed Pharmaceuticals Inc said its oral insulin capsule appeared to be safe and was well-tolerated by diabetics in a mid-stage trial.

The Israeli biotechnology company’s shares jumped about 10 percent to .73 before the bell on Wednesday.

The treatment, ORMD-0801, was being tested in 25 patients with type 1 diabetes, once known as juvenile diabetes.

It is a chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow sugar to enter cells to produce energy.

ORMD-0801 is also being developed for use in type 2 diabetes, the most common form of the disease, where the body does not use insulin properly.

(Reporting by Natalie Grover in Bangalore)

Read the original here:
feeds.reuters

Healthy Living News From around The Web
Oramed’s oral insulin succeeds in study, shares jump – Reuters

Google+

Dopps Chiropractic
4746 S. Broadway
WichitaKs 67216

(316) 522-1122
http://ift.tt/14R1IJ3
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s